SQA Regulatory Surveillance Summary | 3Q/4Q 2025

Regulatory surveillance summary graphic for pharmaceutical compliance updates in Q3 and Q4 2025, highlighting global agencies including FDA, EMA, ANVISA, and WHO.

Staying informed on the latest pharmaceutical compliance updates is essential for navigating an increasingly complex global regulatory landscape. From evolving GMP requirements and regulatory guidance to enforcement actions and emerging risks, these updates directly impact how organizations manage quality, ensure compliance, and protect patient safety. This summary highlights key developments across major health authorities and […]

SQA Regulatory Surveillance Summary | July 2020

Coronavirus Regulatory Guidance and Emergency Measures – July 2020 This regulatory surveillance summary reviews key global regulatory developments from July 2020, including coronavirus guidance, emergency regulatory measures, and compliance considerations. By Laurel Hacche and Debra Cortner, SQA Associates European Medicines Agenda (EMA) Parenteral Drug Association (PDA) News – EMA: Final Assessment Report on Nitrosamines, 22 […]